Tag: MMEN.C
-
Cresco Labs (CL.C) reprices Origin House (OH.C) acquisition terms to match declining market
Cresco Labs (CL.C) and Origin House (OH.C) have updated the terms of their $1.1B acquisition, repricing the all-stock transaction to match declining share prices since the deal’s announcement in April. Pursuant to the Amendment, the consideration payable under the Arrangement will be reduced from 0.8428 of a subordinate voting share of Cresco Labs (a “Cresco…
-
MedMen (MMEN.C) yearly loss was $1m more than Supreme Cannabis’ (FIRE.T) entire market cap
“Fiscal 2019 was a transformative year for Medmen, with over two million completed retail transactions to date and revenues increasing 227% year-over-year,” said Adam Bierman, Medmen co-founder and chief executive officer in a news release that should see the company gutted on the markets Tuesday. Despite Bierman’s attempts at turd polishing, you don’t have to…
-
Deals being reversed across the board as weed companies discover fiscal responsibility
Sometimes a deal broken is a good deal for shareholders, especially if you give a red rat’s behind about your favourite company having enough money to survive the year. Lately, we’re seeing a lot of deals that, at one time, were announced with much fanfare, being quietly dropkicked off the bridge as once high flying…
-
Jim Cramer likes Cronos (CRON.C) more than Canopy Growth (WEED.T), but should you?
In late August, Jim Cramer, host of CNBC’s Mad Money program, said he believes Cronos Group (CRON.C), and Aphria (APHA.T) are better investments than Canopy Growth (WEED.T). Cramer pointed to Canopy’s disappointing Q2 performance as evidence the largest Canadian cannabis player had lost a step. (On Canopy): “That was a terrible quarter. It was a terrible quarter, they still have…
-
Marijuana Update: Ravenquest (RQB.V), CROP (CROP.C), Lifestyle Delivery Systems (LDS.C), iAnthus (IAN.C), and trust
The ability to trust the people you put your money into is of utmost importance. ‘Management’ is oft cited as one of the pillars of a company’s success, but management in this instance could also be defined as ‘trust’. If I asked to borrow money from you in the street, your ability to trust me…
-
Shell Game: How Wayland Group (WAYL.C) built a paper empire and the loan that may drag it under
PROLOGUE: Cannabis companies, as we know them in our minds, rarely exist. Oh sure, some have buildings and staff, some grow things and others might even have a license. But even those with big buildouts and massive market caps are, for the most part, a promise of what’s to come, maybe, some time, kinda. But…
-
![MedMen (MMEN.C) Q3, 2019 revenues and a devastating Rolling Stone article]()
MedMen (MMEN.C) Q3, 2019 revenues and a devastating Rolling Stone article
It’s true: we do enjoy kicking MedMen (MMEN.C) around. Why do we dislike this grotesquely unprofitable company so intensely? Because Adam Bierman (CEO) and Andrew Modlin (President) are greedy. Not – “I-fly-1st-class-and-pay-my-workers-minimum-wage” greedy. Not – “I-cheat-on-my-taxes” greedy. Not – “I’m-unloading-cheap-paper-through-a-numbered-company” greedy. Crazy, almost psychopathically greedy. We dislike them for the same reason we dislike Namaste’s…
-
Cannara Biotech (LOVE.C) makes MedMen look like a charitable institution
Cannara Biotech (LOVE.C) is a pig. I mean, okay. Pigs are actually kind of cool, they’re smart and bacon tastes good and they like a tummy rub, so Cannara is not actually a pig. But it is a trap for your money, and you should ideally not play with money traps because their sole purpose is,…
-
Gamechanger: iAnthus (IAN.C) and MPX Bioceutical (MPX.C) to merge, go after MedMen (MMEN.C)
A week ago, US dispensary roll-up play MedMen (MMEN.C) closed an $86m financing and a $99.95m loan to help them complete a $682m deal to buy PharmaCann, which has ten dispensaries and three weed grows. It was big news and propelled MMEN stock, which many deem to be overpriced before the deal, substantially higher still.…
-
MedMen (MMEN.C) blows out stock to buy 10 dispensaries, three weed farms in Pharmacann deal
In news that pushed MedMen’s (MMEN.C) share price to new highs, the red shirt crew have announced they’re buying US based Pharmacann LLC for $682 million… or, rather, $682 million of MMEN stock, as of October 9. Mind you, the news drove the company share price up significantly, meaning the actual price now being paid…
